Celgene pays $450m for AZ's MEDI4736 in blood cancers; AZ signs $250m+ Innate deal

 
• By Lucie Ellis-Taitt

Celgene is paying AstraZeneca $450m up front in order to develop the UK drug maker's anti-PD-L1 product MEDI4736 in a range of blood cancers – a partnership Celgene thinks could be a "meaningful" driver of growth past 2020.

More from Anticancer

More from Therapy Areas